Biodesix, Inc. (NASDAQ:BDSX) Shares Bought by Barclays PLC

Barclays PLC grew its stake in shares of Biodesix, Inc. (NASDAQ:BDSX) by 1,140.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,036 shares of the company’s stock after acquiring an additional 21,179 shares during the period. Barclays PLC’s holdings in Biodesix were worth $41,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Perceptive Advisors LLC acquired a new stake in shares of Biodesix during the 2nd quarter valued at approximately $3,326,000. Farallon Capital Management LLC acquired a new position in shares of Biodesix during the 2nd quarter worth approximately $2,874,000. CVI Holdings LLC acquired a new position in shares of Biodesix during the 2nd quarter worth approximately $59,000. Perkins Capital Management Inc. raised its position in shares of Biodesix by 74.7% during the 3rd quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock worth $1,290,000 after purchasing an additional 310,000 shares during the last quarter. Finally, Landscape Capital Management L.L.C. acquired a new position in shares of Biodesix during the 3rd quarter worth approximately $262,000. 20.96% of the stock is currently owned by institutional investors and hedge funds.

Biodesix Stock Down 14.2 %

BDSX stock opened at $1.27 on Friday. The stock has a market capitalization of $184.74 million, a P/E ratio of -3.26 and a beta of 1.10. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40. Biodesix, Inc. has a one year low of $1.11 and a one year high of $2.21. The company has a 50 day moving average price of $1.39 and a two-hundred day moving average price of $1.59.

Biodesix (NASDAQ:BDSX) last released its earnings results on Friday, November 1st. The company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. The firm had revenue of $18.15 million during the quarter, compared to analysts’ expectations of $18.45 million. During the same period in the previous year, the company earned ($0.12) EPS. As a group, sell-side analysts expect that Biodesix, Inc. will post -0.35 EPS for the current year.

Insider Activity

In other Biodesix news, Director Jack W. Schuler purchased 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The stock was purchased at an average cost of $1.17 per share, with a total value of $234,000.00. Following the transaction, the director now owns 31,094,935 shares in the company, valued at approximately $36,381,073.95. This trade represents a 0.65 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Matthew Strobeck purchased 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were acquired at an average cost of $1.40 per share, with a total value of $56,000.00. Following the completion of the transaction, the director now owns 2,606,879 shares in the company, valued at $3,649,630.60. This trade represents a 1.56 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased 315,000 shares of company stock valued at $393,500 in the last ninety days. Company insiders own 69.20% of the company’s stock.

Analysts Set New Price Targets

Separately, Scotiabank assumed coverage on Biodesix in a research report on Monday, September 16th. They set a “sector outperform” rating and a $3.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $3.06.

Biodesix Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.